Cover Image
市場調查報告書

腺病毒感染的開發中產品分析

Adenovirus Infections - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 245958
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
腺病毒感染的開發中產品分析 Adenovirus Infections - Pipeline Review, H1 2014
出版日期: 2014年06月15日 內容資訊: 英文 64 Pages
簡介

所謂腺病毒感染是以腺病毒為病原菌的感染疾病,尤其上呼吸道容易受到侵襲。病毒為接觸到帶原者的鼻、喉分泌物,或有病毒附著的物體表面而傳染。主要症狀有鼻涕·鼻塞和喉嚨痛、眼皮內側發炎、肺泡發病(肺炎)、耳朵感染、發燒等。

本報告提供全球各國治療腺病毒(ADV)感染疾病用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

腺病毒感染概要

治療藥的開發

  • 腺病毒感染開發中產品:概要
  • 腺病毒感染開發中產品:比較分析

各企業開發中的腺病毒感染治療藥

大學/研究機關研究中的腺病毒感染治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

腺病毒感染治療藥:開發中的產品一覽(各企業)

腺病毒感染治療藥:研究中的產品一覽(大學/研究機關別)

腺病毒感染治療藥的開發企業

  • NovaBay Pharmaceuticals, Inc.
  • Cell Medica Limited
  • Chimerix, Inc.
  • Foresight Biotherapeutics, Inc.
  • BioApex, s.r.o.

腺病毒感染:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • brincidofovir
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • FST-100
  • Cell Therapy for Infectious Diseases
  • Cytovir ADV
  • Multi-Virus Cytotoxic T Lymphocytes
  • NVC-727
  • BA-368
  • RKP-00156
  • hCAP-18/LL-37

腺病毒感染治療藥:開發中產品的最新趨勢

腺病毒感染治療藥:暫停開發的產品

腺病毒感染相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5145IDB

Global Markets Direct's, 'Adenovirus Infections - Pipeline Review, H1 2014', provides an overview of the Adenovirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenovirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenovirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Adenovirus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Adenovirus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Adenovirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Adenovirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Adenovirus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Adenovirus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adenovirus Infections Overview
  • Therapeutics Development
    • Pipeline Products for Adenovirus Infections - Overview
    • Pipeline Products for Adenovirus Infections - Comparative Analysis
  • Adenovirus Infections - Therapeutics under Development by Companies
  • Adenovirus Infections - Therapeutics under Investigation by Universities/Institutes
  • Adenovirus Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Adenovirus Infections - Products under Development by Companies
  • Adenovirus Infections - Products under Investigation by Universities/Institutes
  • Adenovirus Infections - Companies Involved in Therapeutics Development
    • NovaBay Pharmaceuticals, Inc.
    • Cell Medica Limited
    • Chimerix, Inc.
    • Foresight Biotherapeutics, Inc.
    • BioApex, s.r.o.
  • Adenovirus Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • brincidofovir - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FST-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cytovir ADV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Multi-Virus Cytotoxic T Lymphocytes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVC-727 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BA-368 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RKP-00156 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hCAP-18/LL-37 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Adenovirus Infections - Recent Pipeline Updates
  • Adenovirus Infections - Dormant Projects
  • Adenovirus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Mar 14, 2014: Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection
      • Mar 11, 2014: Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections
      • Sep 11, 2013: Chimerix Presents Brincidofovir Adenovirus Phase 2 Results
      • Aug 14, 2013: Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC
      • May 16, 2013: Chimerix Presents Data On CMX001 At 26th International Conference On Antiviral Research
      • Apr 29, 2013: Chimerix Presents Data On Antiviral Drug Candidate CMX001 At EBMT Annual Meeting
      • Apr 08, 2013: NovaBay Pharma Enrolls First Patients In Brazil In BAYnovation Phase IIb Study For Adenoviral Conjunctivitis
      • Mar 28, 2013: Chimerix Announces Presentation Of Data On Antiviral Compound CMX001 At EBMT Annual Meeting
      • Apr 03, 2012: Chimerix To Present Data On CMX001 At Needham And Future Leaders Conferences
      • Jan 23, 2012: NovaBay Prepares To Launch Global Phase IIb Ophthalmic Study Of NVC-422
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Adenovirus Infections, H1 2014
  • Number of Products under Development for Adenovirus Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Adenovirus Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2014
  • Adenovirus Infections - Pipeline by Cell Medica Limited., H1 2014
  • Adenovirus Infections - Pipeline by Chimerix, Inc., H1 2014
  • Adenovirus Infections - Pipeline by Foresight Biotherapeutics, Inc., H1 2014
  • Adenovirus Infections - Pipeline by BioApex, s.r.o., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Adenovirus Infections Therapeutics - Recent Pipeline Updates, H1 2014
  • Adenovirus Infections - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Adenovirus Infections, H1 2014
  • Number of Products under Development for Adenovirus Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top